Terumo Corp
TSE:4543
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 129.2177
3 160
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Terumo Corp
Terumo Corp
Net Income (Common)
Terumo Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Terumo Corp
TSE:4543
|
Net Income (Common)
¥119.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Olympus Corp
TSE:7733
|
Net Income (Common)
¥75.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Sysmex Corp
TSE:6869
|
Net Income (Common)
¥53.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Net Income (Common)
¥9.5B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
JEOL Ltd
TSE:6951
|
Net Income (Common)
¥25.1B
|
CAGR 3-Years
66%
|
CAGR 5-Years
34%
|
CAGR 10-Years
21%
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Net Income (Common)
¥16.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Terumo Corp
Glance View
In the bustling corridors of Tokyo, Terumo Corporation stands as a testament to Japan's prowess in medical innovation, deeply rooted in a legacy that began over 90 years ago. Born from the vision of a group of scientists aiming to improve Japan’s healthcare system, Terumo embarked on its journey by developing high-quality thermometers. This modest start set the stage for what would become a global leader in medical technology. Anchored by its commitment to enhancing patient care and healthcare practices, Terumo carved out a significant niche by focusing on cardiovascular systems, blood transfusion, and cell therapy technologies. As the company grew, it systematically increased its range, moving into areas such as vascular intervention and diabetes care, aligning with evolving medical needs around the globe. Today, Terumo generates its revenue through a multi-faceted business model that thrives on innovation and globalization. It operates through several segments: Cardiovascular, General Hospital, and Blood Management. The Cardiovascular division, a major revenue driver, offers products ranging from stents to heart-lung machines used in cardiac surgeries. Meanwhile, the General Hospital unit provides hospital equipment like infusion pumps and syringe systems, while the Blood Management segment is renowned for its blood and cell processing systems. Terumo’s ability to innovate within these domains enhances its competitive edge by delivering cutting-edge medical solutions. By balancing its expansive product portfolio with a strong focus on research and development, the company not only sustains but frequently advances the standards of modern healthcare, ensuring its continued success in diverse international markets.
See Also
What is Terumo Corp's Net Income (Common)?
Net Income (Common)
119.5B
JPY
Based on the financial report for Sep 30, 2024, Terumo Corp's Net Income (Common) amounts to 119.5B JPY.
What is Terumo Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
13%
Over the last year, the Net Income (Common) growth was 21%. The average annual Net Income (Common) growth rates for Terumo Corp have been 8% over the past three years , 6% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
